Free Trial

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S logo
$52.02 +0.66 (+1.28%)
As of 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
1
Buy
11

Based on 12 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$53.50
2.84% Upside
According to the 12 analysts' twelve-month price targets for Genmab A/S, the average price target is $53.50. The highest price target for GMAB is $80.00, while the lowest price target for GMAB is $32.00. The average price target represents a forecasted upside of 2.84% from the current price of $52.03.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$53.50$42.50$39.50$39.75
Forecasted Upside2.84% Upside14.86% Upside19.84% Upside31.36% Upside
Consensus RatingBuyModerate BuyModerate BuyModerate Buy

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SHealthcare CompaniesBroader Market
Consensus Rating Score
3.00
2.32
2.52
Consensus RatingBuyHoldModerate Buy
Predicted Upside4.15% Upside115.11% Upside14.68% Upside
News Sentiment Rating
Neutral News

See Recent GMAB News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/13/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Judah Frommer
Judah Frommer
5 of 5 stars
Lower TargetEqual Weight$57.00 ➝ $56.00+9.72%
11/9/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeHold (C+) ➝ Buy (B-)
10/30/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Michael Schmidt
Michael Schmidt
5 of 5 stars
Boost TargetBuy$58.00 ➝ $80.00+36.72%
10/29/2026Reiterated RatingBuy$45.00 ➝ $67.00+16.90%
10/29/2026Boost TargetBuy$50.00 ➝ $70.00+22.19%
10/26/2026Boost TargetBuy$43.00 ➝ $52.00+17.64%
10/26/2026UpgradeNeutral ➝ Overweight
7/22/2026 Set Target$43.00+51.62%
4/22/2026 UpgradeHold ➝ Strong-Buy
4/22/2026 UpgradeNeutral ➝ Buy
3/27/2026Initiated CoverageOutperform$32.00+22.94%
3/2/2026Initiated CoverageOverweight$40.00+35.87%
2/17/2026Initiated CoverageBuy$41.50+38.20%
10/31/2025 DowngradeStrong-Buy ➝ Hold
10/27/2025 Reiterated RatingBuy
4/1/2025DowngradeMarket Perform ➝ Underperform
3/11/2025UpgradeMarket Perform ➝ Outperform
2/13/2025UpgradeMarket Perform ➝ Outperform$27.00+37.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:16 AM ET.


Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 12, 2026. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Genmab A/S recently reported third-quarter earnings of $0.56 per share, significantly beating the consensus estimate of $0.36 by $0.20, which demonstrates strong profitability and operational efficiency that can drive shareholder value.
  • The stock is currently trading at $51.74, which is well above its 50-day moving average of $40.46 and 200-day moving average of $31.43, indicating a strong upward momentum and positive technical trend for investors.
  • Analysts have recently raised their price targets, with HC Wainwright increasing its target to $70.00 and Guggenheim to $80.00, reflecting a consensus "Moderate Buy" rating and high confidence in the company's future growth potential.
  • Unusually high call option buying was observed, with 24,213 call options traded compared to a typical daily volume of 4,137, suggesting that traders are positioning for further price appreciation in the near term.
  • Short interest has decreased significantly, with the short-interest ratio dropping to 1.2 days to cover, indicating that fewer investors are betting against the stock and reducing the potential for a short squeeze that could drive prices higher.

Genmab A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Genmab A/S for these reasons:

  • HC Wainwright recently lowered its full-year 2026 earnings estimate from $1.51 to $1.46 per share, signaling potential challenges in maintaining the high growth rate seen in previous quarters.
  • The stock's price-to-earnings ratio of 41.44 is relatively high, which may indicate that the stock is overvalued compared to its current earnings, posing a risk if growth slows down.
  • Genmab A/S does not pay a dividend, with a dividend yield of 0.00%, which may be a drawback for income-focused investors seeking regular cash flow from their investments.
  • The company's revenue of $1.19 billion in the latest quarter slightly missed analyst expectations of $1.20 billion, suggesting potential headwinds in top-line growth that could impact future earnings.
  • Short interest increased by 46.4% in October, with 9,659,086 shares shorted, indicating that some investors are skeptical about the stock's future performance and may be positioning for a decline.

GMAB Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $53.50, with a high forecast of $80.00 and a low forecast of $32.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There is currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GMAB shares.

According to analysts, Genmab A/S's stock has a predicted upside of 2.84% based on their 12-month stock forecasts.

Over the previous 90 days, Genmab A/S's stock had 3 upgrades by analysts.

Genmab A/S has been rated by research analysts at Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, TD Cowen, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Genmab A/S more than other "healthcare" companies. The consensus rating for Genmab A/S is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how GMAB compares to other companies.


MarketBeat monitors more than a dozen sources for Genmab A/S analyst ratings, with the most recent rating issued on 11/13/2026.
From Our Partners